Adebrelimab plus chemotherapy for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has spread or cannot be removed by surgery.
- Your cancer has gotten worse after at least one prior chemotherapy (but you haven't had gemcitabine or immunotherapy).
- You are between 18 and 75 years old and have a good performance status (ECOG 0-1, meaning you can do daily activities).
- You have at least one tumor that can be measured on scans, and your doctor expects you to live more than 3 months.
- Your blood counts, liver, kidney, and heart function are within acceptable ranges on lab tests.
- You are not pregnant, and you agree to use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the drug Adebrelimab to standard care for people with pancreatic cancer that has caused fluid buildup around the lungs or in the belly (called pleural or peritoneal effusions). The goal is to see if this combination can help control the cancer better.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests a combination of immunotherapy (adebelimab) and chemotherapy drugs (irinotecan liposome, oxaliplatin, fluorouracil, and calcium folinate) as a first treatment for pancreatic cancer that has spread to the liver. The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Hear when a new Pancreatic Cancer Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.